Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition

Behavioural Brain Research

Volumn 301, Issue , 2016, Pages 204-212

  Miyauchi, Masanori ^a,b   Neugebauer, Nichole M ^a   Oyamada, Yoshihiro ^a,b   Meltzer, Herbert Y ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Acetylcholine; Atypical antipsychotic drug; Nicotinic acetylcholine receptors; Novel object recognition; Phencyclidine

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; 4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; ACETYLCHOLINE; BUNGAROTOXIN RECEPTOR; DIHYDRO BETA ERYTHROIDINE; LURASIDONE; MECAMYLAMINE; METHYLLYCACONITINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; PHENCYCLIDINE; AZETIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; BRIDGED BICYCLO COMPOUNDS; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; PNU-282987;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG POTENTIATION; FEMALE; LONG EVANS RAT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; RECOGNITION; SCHIZOPHRENIA; ANIMAL; COGNITION DISORDERS; DISEASE MODEL; METABOLISM; RANDOMIZATION;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; AZETIDINES; BENZAMIDES; BRIDGED BICYCLO COMPOUNDS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; LURASIDONE HYDROCHLORIDE; MECAMYLAMINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; NOOTROPIC AGENTS; PHENCYCLIDINE; RANDOM ALLOCATION; RATS, LONG-EVANS; RECEPTORS, NICOTINIC;

EID: 84952879598     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.10.044     Document Type: Article

References (56)

1. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999, 25:233-256.
2. Meltzer H.Y. Pharmacotherapy of cognition in schizophrenia. Curr. Opin. Behav. Sci. 2015, 4:115-121.
3. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8:457-472.
4. Harvey P.D., Ogasa M., Cucchiaro J., Loebel A., Keefe R.S. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr. Res. 2011, 127:188-194.
5. Keefe R.S., Silva S.G., Perkins D.O., Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 1999, 25:201-222.
6. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2002, 159:1018-1028.
7. Meltzer H.Y., Rajagopal L., Huang M., Oyamada Y., Kwon S., Horiguchi M. Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol. 2013, 16:2181-2194.
8. Ennaceur A. One-trial object recognition in rats and mice: methodological and theoretical issues. Behav. Brain Res. 2010, 215:244-254.
9. Manns J.R., Stark C.E., Squire L.R. The visual paired-comparison task as a measure of declarative memory. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:12375-12379.
10. Neill J.C., Barnes S., Cook S., Grayson B., Idris N.F., McLean S.L., et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol. Ther. 2010, 128:419-432.
11. Snigdha S., Horiguchi M., Huang M., Li Z., Shahid M., Neill J.C., et al. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J. Pharmacol. Exp. Ther. 2010, 332:622-631.
12. Horiguchi M., Huang M., Meltzer H.Y. The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J. Pharmacol. Exp. Ther. 2011, 338:605-614.
13. Ishibashi T., Horisawa T., Tokuda K., Ishiyama T., Ogasa M., Tagashira R., et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 2010, 334:171-181.
14. Huang M., Panos J.J., Kwon S., Oyamada Y., Rajagopal L., Meltzer H.Y. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT) 2A and DA D2 antagonism and 5-HT1A partial agonism. J. Neurochem. 2014, 128:938-949.
15. Ikonen S., McMahan R., Gallagher M., Eichenbaum H., Tanila H. Cholinergic system regulation of spatial representation by the hippocampus. Hippocampus 2002, 12:386-397.
16. Colgin L.L. Oscillations and hippocampal-prefrontal synchrony. Curr. Opin. Neurobiol. 2011, 21:467-474.
17. MacDermott A.B., Role L.W., Siegelbaum S.A. Presynaptic ionotropic receptors and the control of transmitter release. Annu. Rev. Neurosci. 1999, 22:443-485.
18. Huang M., Felix A.R., Flood D.G., Bhuvaneswaran C., Hilt D., Koenig G., et al. The novel alpha7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology 2014, 231:4541-4551.
19. Guan Z.Z., Zhang X., Blennow K., Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 1999, 10:1779-1782.
20. Newhouse P.A., Potter A., Corwin J., Lenox R. Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology 1992, 108:480-484.
21. Rusted J.M., Warburton D.M. The effects of scopolamine on working memory in healthy young volunteers. Psychopharmacology 1988, 96:145-152.
22. Nathan P.J., Watson J., Lund J., Davies C.H., Peters G., Dodds C.M., et al. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int. J. Neuropsychopharmacol. 2013, 16:721-731.
23. Levin E.D., McClernon F.J., Rezvani A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 2006, 184:523-539.
24. Harris J.G., Kongs S., Allensworth D., Martin L., Tregellas J., Sullivan B., et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 2004, 29:1378-1385.
25. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dube S., Mallinckrodt C., et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 2008, 165:1033-1039.
26. Shim J.C., Jung D.U., Jung S.S., Seo Y.S., Cho D.M., Lee J.H., et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2012, 37:660-668.
27. Preskorn S.H., Gawryl M., Dgetluck N., Palfreyman M., Bauer L.O., Hilt D.C. Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J. Psychiatr. Pract. 2014, 20:12-24.
28. Keefe R., Meltzer H.Y., Dgetluck N., Gawryl M., Koenig G., Moebius H., et al. Randomized, double-blind, placebo-controlled study of encenicline, an alpha-7 nicotinic acetylcholine receptor partial agonist as a treatment for cognitive impairment in schizophrenia. Neuropsychopharmacology 2015, 40(13):3053-3060.
29. Weiner D.M., Meltzer H.Y., Veinbergs I., Donohue E.M., Spalding T.A., Smith T.T., et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 2004, 177:207-216.
30. Marquis K.L., Comery T.A., Jow F., Navarra R.L., Grauer S.M., Pulicicchio C., et al. Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. Psychopharmacology 2011, 218:635-647.
31. Grottick A.J., Higgins G.A. Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. Behav. Brain Res. 2000, 117:197-208.
32. Pandya A.A., Yakel J.L. Activation of the alpha7 nicotinic ACh receptor induces anxiogenic effects in rats which is blocked by a 5-HT(1) a receptor antagonist. Neuropharmacology 2013, 70:35-42.
33. Schreiber R., Dalmus M., De Vry J. Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology 2002, 159:248-257.
34. Jentsch J.D., Taylor J.R. Impaired inhibition of conditioned responses produced by subchronic administration of phencyclidine to rats. Neuropsychopharmacology 2001, 24:66-74.
35. Kruk-Slomka M., Michalak A., Budzynska B., Biala G. A comparison of mecamylamine and bupropion effects on memory-related responses induced by nicotine and scopolamine in the novel object recognition test in mice. Pharmacol. Rep. 2014, 66:638-646.
36. Young J.W., Meves J.M., Tarantino I.S., Caldwell S., Geyer M.A. Delayed procedural learning in alpha7-nicotinic acetylcholine receptor knockout mice. Genes Brain Behav. 2011, 10:720-733.
37. Zanardi A., Ferrari R., Leo G., Maskos U., Changeux J.P., Zoli M. Loss of high-affinity nicotinic receptors increases the vulnerability to excitotoxic lesion and decreases the positive effects of an enriched environment. FASEB J. 2007, 21:4028-4037.
38. Chavez-Noriega L.E., Crona J.H., Washburn M.S., Urrutia A., Elliott K.J., Johnson E.C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1997, 280:346-356.
39. Tinsley C.J., Fontaine-Palmer N.S., Vincent M., Endean E.P., Aggleton J.P., Brown M.W., et al. Differing time dependencies of object recognition memory impairments produced by nicotinic and muscarinic cholinergic antagonism in perirhinal cortex. Learn. Mem. (Cold Spring Harbor, N.Y.) 2011, 18:484-492.
40. Chung Y.C., Li Z., Dai J., Meltzer H.Y., Ichikawa J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Res. 2004, 1023:54-63.
41. Shirazi-Southall S., Rodriguez D.E., Nomikos G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 2002, 26:583-594.
42. Ichikawa J., Li Z., Dai J., Meltzer H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res. 2002, 956:349-357.
43. Horiguchi M., Hannaway K.E., Adelekun A.E., Jayathilake K., Meltzer H.Y. Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. Neuropsychopharmacology 2012, 37:2175-2183.
44. Li Z., Prus A.J., Dai J., Meltzer H.Y. Differential effects of M1 and 5-hydroxytryptamine1A receptors on atypical antipsychotic drug-induced dopamine efflux in the medial prefrontal cortex. J. Pharmacol. Exp. Ther. 2009, 330:948-955.
45. Castner S.A., Smagin G.N., Piser T.M., Wang Y., Smith J.S., Christian E.P., et al. Immediate and sustained improvements in working memory after selective stimulation of alpha7 nicotinic acetylcholine receptors. Biol. Psychiatry 2011, 69:12-18.
46. Barak S., Arad M., De Levie A., Black M.D., Griebel G., Weiner I. Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia. Neuropsychopharmacology 2009, 34:1753-1763.
47. Hashimoto K., Ishima T., Fujita Y., Matsuo M., Kobashi T., Takahagi M., et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol. Psychiatry 2008, 63:92-97.
48. Roh S., Hoeppner S.S., Schoenfeld D., Fullerton C.A., Stoeckel L.E., Evins A.E. Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia. Psychopharmacology 2014, 231:765-775.
49. Jenkins T.A., Harte M.K., Reynolds G.P. Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat. Neurosci. Lett. 2010, 471:144-147.
50. Abdul-Monim Z., Neill J.C., Reynolds G.P. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J. Psychopharmacol. (Oxford, England) 2007, 21:198-205.
51. Nomura T., Oyamada Y., Fernandes H., Remmers C., Xu J., Meltzer H., et al. Subchronic phencyclidine causes adaptive changes in GABAergic transmission and LTP threshold in the hippocampus. Neuropharmacology 2015, 100:90-97.
52. Alkondon M., Pereira E.F., Eisenberg H.M., Albuquerque E.X. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CA1 interneurons in rat hippocampal slices. J. Neurosci. 1999, 19:2693-2705.
53. Yan Z. Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications. Mol. Neurobiol. 2002, 26:203-216.
54. Szabadics J., Varga C., Molnar G., Olah S., Barzo P., Tamas G. Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits. Science (New York, N.Y.) 2006, 311:233-235.
55. Yuen E.Y., Li X., Wei J., Horiguchi M., Meltzer H.Y., Yan Z. The novel antipsychotic drug lurasidone enhances N-methyl-d-aspartate receptor-mediated synaptic responses. Mol. Pharmacol. 2012, 81:113-119.
56. Luoni A., Hulsken S., Cazzaniga G., Racagni G., Homberg J.R., Riva M.A. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats. Int. J. Neuropsychopharmacol. 2013, 16:1319-1330.